Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus ...
The partners will incorporate Telix's PSMA-PET gallium 68-based imaging agents Gozellix and Illuccix with EDAP and Profound's technologies for minimally invasive treatment.
Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results